PMID- 20103725
OWN - NLM
STAT- MEDLINE
DCOM- 20100423
LR  - 20151119
IS  - 1940-6215 (Electronic)
IS  - 1940-6215 (Linking)
VI  - 3
IP  - 2
DP  - 2010 Feb
TI  - Cyclooxygenase-2 inhibition for the prophylaxis and treatment of preinvasive 
      breast cancer in a her-2/neu mouse model.
PG  - 202-11
LID - 10.1158/1940-6207.CAPR-09-0181 [doi]
AB  - Ductal carcinoma in situ (DCIS) is the most common form of preinvasive breast 
      cancer. Several molecular alterations have been identified in DCIS. Among them, 
      cyclooxygenase 2 (COX-2) overexpression has been shown in 60% to 80% of DCIS 
      cases. Celecoxib is a nonsteroidal anti-inflammatory drug that selectively 
      inhibits COX-2. In this study, we evaluated whether COX-2 inhibition by celecoxib 
      can reduce the incidence of preinvasive breast cancer and its progression to 
      invasive breast cancer in a mouse model exhibiting a similar phenotype to human 
      solid-pattern DCIS. We have used the mouse model mouse mammary tumor virus 
      (MMTV)-Neu to investigate this possibility. These mice carry a rat Her-2/Neu 
      transgene and are known to develop DCIS-like lesions. Our results showed that 
      celecoxib (500 ppm) given as prophylaxis was neither able to prevent tumor 
      development nor delay tumor appearance compared with untreated mice. Furthermore, 
      when the drug was given early in tumorigenesis, it did not reduce the progression 
      of preinvasive to invasive tumors nor prevent lung metastasis. Reduction of 
      prostaglandin levels was, however, achieved in mammary tumors of treated mice. In 
      addition, celecoxib treatment caused an increase in apoptosis and decreased 
      vascular endothelial growth factor expression in treated animals. Our results 
      contrast with some previously published studies and highlight the complexity of 
      the relationship between COX-2 and breast cancer.
FAU - Tran-Thanh, Danh
AU  - Tran-Thanh D
AD  - Ontario Cancer Institute, University Health Network, Toronto, Canada.
FAU - Buttars, Stephen
AU  - Buttars S
FAU - Wen, Yanxia
AU  - Wen Y
FAU - Wilson, Christine
AU  - Wilson C
FAU - Done, Susan J
AU  - Done SJ
LA  - eng
GR  - MOP-68980/Canadian Institutes of Health Research/Canada
GR  - STP-53912/Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100126
PL  - United States
TA  - Cancer Prev Res (Phila)
JT  - Cancer prevention research (Philadelphia, Pa.)
JID - 101479409
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Pyrazoles)
RN  - 0 (Sulfonamides)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - JCX84Q7J1L (Celecoxib)
RN  - K7Q1JQR04M (Dinoprostone)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*pharmacology
MH  - Apoptosis/drug effects
MH  - Breast Neoplasms/pathology/*prevention & control
MH  - Carcinoma in Situ/*drug therapy/pathology
MH  - Carcinoma, Ductal, Breast/pathology/*prevention & control
MH  - Celecoxib
MH  - Cyclooxygenase 2/drug effects
MH  - Dinoprostone/analysis/metabolism
MH  - Disease Models, Animal
MH  - Disease Progression
MH  - Enzyme Inhibitors/pharmacology
MH  - Female
MH  - Genes, erbB-2
MH  - Immunohistochemistry
MH  - Mice
MH  - Mice, Transgenic
MH  - Pyrazoles/*pharmacology
MH  - Sulfonamides/*pharmacology
MH  - Vascular Endothelial Growth Factor A/analysis/drug effects/metabolism
EDAT- 2010/01/28 06:00
MHDA- 2010/04/24 06:00
CRDT- 2010/01/28 06:00
PHST- 2010/01/28 06:00 [entrez]
PHST- 2010/01/28 06:00 [pubmed]
PHST- 2010/04/24 06:00 [medline]
AID - 1940-6207.CAPR-09-0181 [pii]
AID - 10.1158/1940-6207.CAPR-09-0181 [doi]
PST - ppublish
SO  - Cancer Prev Res (Phila). 2010 Feb;3(2):202-11. doi: 
      10.1158/1940-6207.CAPR-09-0181. Epub 2010 Jan 26.